Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults (CES-MDD)

Fisher Wallace Laboratories

Status: Completed

Conditions: Major Depressive Disorder

Treatments: Device: Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device); Device: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05384041

FW-200-05

Details and patient eligibility

About

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

Full description

This prospective, fully remote, randomized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

Enrollment: 255 patients

Sex: All

Ages: 21 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 21-65 years and a resident of the United States of America
2. Meets DSM-5 diagnostic criteria for moderate to severe Major Depressive Disorder
3. Baseline BDI-II score between 20 and 63, inclusive (in moderate to severe range)
4. Able to receive packages to their home via United Parcel Service/Fedex/United States Postal Service or other delivery service
5. Willing and able to send and receive study related text messages on an internet capable mobile device throughout the duration of the study
6. Owns and uses a personal, verifiable email address
7. Able to commit to two (2) 20-minute treatment sessions per day for 4 weeks, one treatment upon waking for the day and one treatment before going to bed
8. Willing to abstain from use of recreational drugs, hypnotics, steroids, and/or marijuana products through study completion
9. Willingness to not initiate treatment for a mental health issue during the course of the study
10. Fluent in English
11. Sexually active females of childbearing potential willing to commit to practicing at least one or more of the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception, or abstinence
12. In the opinion of the investigator, able to comply with study requirements and complete the study

Exclusion criteria

1. History of suicide attempt or active suicidal ideation with plan or intent in the past 30 days.
2. In the opinion of the investigator, considered high risk of suicide
3. Previous hospitalization or institutionalization for mental health condition within one year of study entry
4. Underwent electronic brain stimulation or neuromodulation within the past one year, including CES, transcranial magnetic stimulation, electroconvulsive therapy, and deep brain stimulation
5. Modification of prescription medications that affect the nervous system (e.g., psychotropic medications) within 30 days of study entry
6. Use of recreational drugs, hypnotics, steroids, and/or marijuana products in the past 30 days
7. History of alcohol use disorder or other substance use disorder in the past 12 months
8. Females currently pregnant or planning to conceive during study participation, or unwilling to comply with birth control requirements
9. Known history of heart disease
10. Known history of trigeminal neuralgia
11. Implanted with an electronic device such as a defibrillator, deep brain stimulator, or pacemaker
12. Unstable medical condition including any condition requiring hospitalization or change in treatment in the prior 30 days
13. Legally blind and/or deaf and without in-home care service to assist with study participation
14. Meets M.I.N.I. assessment criteria for, or has been diagnosed with, any of the following: Bipolar I disorder, bipolar II disorder, other specified bipolar and related disorder, panic disorder, agoraphobia, social anxiety disorder (social phobia), obsessive-compulsive disorder, posttraumatic stress disorder, alcohol use disorder in the past 12 months, substance use disorder (non-alcohol) in the past 12 months, any psychotic disorder (e.g., schizophrenia, schizoaffective disorder), major depressive disorder with psychotic features, anorexia nervosa, bulimia nervosa, binge-eating disorder, generalized anxiety disorder, any cognitive or developmental disorder (e.g., autism, Down's Syndrome), any personality disorder or psychiatric disorder that may interfere with study participation
15. Current participation in another investigational study or participated in an investigational study within the past 30 days
16. In the opinion of the investigator, may not be able to comply with study requirements
17. Any employee, family member, or personal associate of the Sponsor or their designees conducting the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

255 participants in 2 patient groups, including a placebo group

Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

Active Comparator group

Description:

The Fisher Wallace Stimulator provides cranial electrotherapy stimulation and is an active device.

Treatment:

Device: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)

Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)

Placebo Comparator group

Description:

The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.

Treatment:

Device: Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)